Heart Disease Clinical Trials in Charlotte, NC

47 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function	Phase 3	AstraZeneca	<1 mi
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)	Phase 3	Anthos Therapeutics, Inc.	<1 mi
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension	Phase 2	Retension Pharmaceuticals. Inc.	<1 mi
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin	Phase 3	AstraZeneca	<1 mi
Reducing Risk for Infective Endocarditis	N/A	Wake Forest University Health Sciences	<1 mi
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2	Phase 3	Mezzion Pharma Co. Ltd	<1 mi
The ENCIRCLE Trial	N/A	Edwards Lifesciences	<1 mi
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention	Phase 4	Duke University	<1 mi
AltaValve Pivotal Trial	N/A	4C Medical Technologies, Inc.	<1 mi
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure	N/A	Abbott Medical Devices	<1 mi
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves	N/A	Edwards Lifesciences	<1 mi
Left vs Left Randomized Clinical Trial	N/A	Baylor College of Medicine	<1 mi
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement	N/A	University of British Columbia	<1 mi
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions	N/A	Boston Scientific Corporation	<1 mi
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy	Phase 3	Alnylam Pharmaceuticals	<1 mi
Assessment of CCM in HF With Higher Ejection Fraction	N/A	Impulse Dynamics	<1 mi
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery	Phase 3	Yale University	<1 mi
Abbott Cephea Mitral Valve Disease Registry	—	Abbott Medical Devices	<1 mi
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment	Phase 2	BioMarin Pharmaceutical	<1 mi
J-Valve Transfemoral Pivotal Study	N/A	JC Medical, Inc., an affiliate of Edwards Lifesciences LLC	<1 mi
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance	—	Minneapolis Heart Institute Foundation	<1 mi
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease	—	Children's Hospital Medical Center, Cincinnati	<1 mi
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure	Phase 4	AstraZeneca	<1 mi
EFS of the CardioMech MVRS	N/A	CardioMech AS	<1 mi
Cephea Early Feasibility Study	N/A	Abbott Medical Devices	<1 mi
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy	Phase 4	Dennis M. McNamara, MD, MS	<1 mi
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II	N/A	Shockwave Medical, Inc.	<1 mi
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study	N/A	Brigham and Women's Hospital	<1 mi
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)	Phase 3	Novartis Pharmaceuticals	<1 mi
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)	Phase 3	Boehringer Ingelheim	<1 mi
PARTNER 3 Trial - Aortic Valve-in-Valve	N/A	Edwards Lifesciences	<1 mi
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy	Phase 2	Imbria Pharmaceuticals, Inc.	<1 mi
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF	Phase 3	Tenax Therapeutics, Inc.	<1 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	<1 mi
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)	—	Bristol-Myers Squibb	<1 mi
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure	N/A	Procyrion	<1 mi
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study	N/A	Wake Forest University Health Sciences	<1 mi
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)	N/A	Wake Forest University Health Sciences	<1 mi
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study	N/A	W.L.Gore & Associates	<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy	Phase 3	Pierre Fabre Medicament	<1 mi
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation	Phase 3	Novo Nordisk A/S	19 mi
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS	Phase 3	DalCor Pharmaceuticals	23 mi
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation	—	Heart Rhythm Clinical and Research Solutions, LLC	23 mi
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study	Phase 2/3	Kardigan, Inc.	23 mi
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)	Phase 2	Tectonic Therapeutic	23 mi
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events	Phase 3	Amgen	24 mi
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart	Phase 3	Boehringer Ingelheim	39 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.